Thus, we hypothesize that an increment of serum CD25 in melanoma patients who respond to anti-PD-1 therapy could be an indicator of an IL-2-mediated T cell activation, predictive of an effective anti-tumor immune response51,55. This evidence concerns the gene IL2 and melanoma.